Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025
Stereotaxis (NYSE: STXS) announced it will showcase the first-ever live demonstration of its GenesisX Robotic System at the Heart Rhythm Symposium (HRS) in San Diego from April 24-27, 2025. The GenesisX system represents a significant advancement in endovascular surgical robotics, featuring a compact design with built-in magnetic shielding and 80% smaller system cabinet that fits under operating room tables.
The system operates on standard power, requires no structural anchoring, and maintains high performance standards. GenesisX received CE Mark approval in Europe in 2024 and is currently under FDA 510(k) review. The company will also display its portfolio of compatible catheters including Map-iT™, MAGiC™, and EMAGIN™, alongside Synchrony™ and SynX™ digital lab technologies.
Stereotaxis (NYSE: STXS) ha annunciato che presenterà la prima dimostrazione dal vivo del suo Sistema Robotico GenesisX al Heart Rhythm Symposium (HRS) a San Diego, dal 24 al 27 aprile 2025. Il sistema GenesisX rappresenta un importante progresso nella robotica chirurgica endovascolare, con un design compatto, schermatura magnetica integrata e un armadio di sistema ridotto dell'80% che si adatta sotto i tavoli operatori.
Il sistema funziona con alimentazione standard, non richiede ancoraggi strutturali e mantiene elevati standard di prestazioni. GenesisX ha ottenuto la certificazione CE in Europa nel 2024 ed è attualmente in fase di revisione FDA 510(k). L'azienda presenterà inoltre il suo portafoglio di cateteri compatibili, tra cui Map-iT™, MAGiC™ ed EMAGIN™, insieme alle tecnologie digitali di laboratorio Synchrony™ e SynX™.
Stereotaxis (NYSE: STXS) anunció que realizará la primera demostración en vivo de su Sistema Robótico GenesisX en el Heart Rhythm Symposium (HRS) en San Diego, del 24 al 27 de abril de 2025. El sistema GenesisX representa un avance significativo en la robótica quirúrgica endovascular, con un diseño compacto, blindaje magnético incorporado y un gabinete del sistema un 80% más pequeño que cabe debajo de las mesas de operaciones.
El sistema funciona con energía estándar, no requiere anclajes estructurales y mantiene altos estándares de rendimiento. GenesisX recibió la aprobación CE en Europa en 2024 y actualmente está bajo revisión FDA 510(k). La compañía también mostrará su portafolio de catéteres compatibles, incluyendo Map-iT™, MAGiC™ y EMAGIN™, junto con las tecnologías digitales de laboratorio Synchrony™ y SynX™.
Stereotaxis (NYSE: STXS)는 2025년 4월 24일부터 27일까지 샌디에이고에서 열리는 Heart Rhythm Symposium(HRS)에서 GenesisX 로봇 시스템의 첫 라이브 시연을 선보일 예정이라고 발표했습니다. GenesisX 시스템은 내혈관 수술용 로봇 분야에서 중요한 발전을 이루었으며, 컴팩트한 디자인과 내장된 자기 차폐 기능, 수술대 아래에 들어가는 크기 대비 80% 작은 시스템 캐비닛을 특징으로 합니다.
이 시스템은 표준 전원으로 작동하며 구조적 고정이 필요 없고 높은 성능 기준을 유지합니다. GenesisX는 2024년에 유럽에서 CE 마크 승인을 받았으며 현재 FDA 510(k) 심사 중에 있습니다. 또한 회사는 Map-iT™, MAGiC™, EMAGIN™을 포함한 호환 카테터 포트폴리오와 Synchrony™ 및 SynX™ 디지털 연구실 기술도 함께 선보일 예정입니다.
Stereotaxis (NYSE : STXS) a annoncé qu'elle présentera la toute première démonstration en direct de son Système Robotique GenesisX lors du Heart Rhythm Symposium (HRS) à San Diego, du 24 au 27 avril 2025. Le système GenesisX représente une avancée majeure dans la robotique chirurgicale endovasculaire, avec un design compact, une protection magnétique intégrée et une armoire système 80 % plus petite qui se glisse sous les tables d’opération.
Le système fonctionne avec une alimentation standard, ne nécessite aucune fixation structurelle et maintient des performances élevées. GenesisX a obtenu le marquage CE en Europe en 2024 et est actuellement en cours d’examen FDA 510(k). L’entreprise présentera également son portefeuille de cathéters compatibles, notamment Map-iT™, MAGiC™ et EMAGIN™, ainsi que les technologies numériques de laboratoire Synchrony™ et SynX™.
Stereotaxis (NYSE: STXS) gab bekannt, dass es die allererste Live-Demonstration seines GenesisX Robotersystems auf dem Heart Rhythm Symposium (HRS) in San Diego vom 24. bis 27. April 2025 zeigen wird. Das GenesisX-System stellt einen bedeutenden Fortschritt in der endovaskulären chirurgischen Robotik dar und zeichnet sich durch ein kompaktes Design mit integrierter magnetischer Abschirmung sowie einem 80 % kleineren Systemschrank aus, der unter OP-Tische passt.
Das System arbeitet mit Standardstrom, benötigt keine strukturelle Verankerung und hält hohe Leistungsstandards ein. GenesisX erhielt 2024 die CE-Kennzeichnung in Europa und befindet sich derzeit in der FDA 510(k)-Prüfung. Das Unternehmen wird außerdem sein Portfolio kompatibler Katheter, darunter Map-iT™, MAGiC™ und EMAGIN™, sowie die digitalen Labortechnologien Synchrony™ und SynX™ präsentieren.
- CE Mark approval obtained in Europe for GenesisX system
- Significant infrastructure cost reduction through built-in magnetic shielding
- 80% smaller system footprint improving operating room efficiency
- System operates on standard power with no structural modifications needed
- FDA approval still pending in the United States
- Revenue impact from GenesisX pending regulatory clearances and market adoption
GenesisX pairs clinical capability with broad accessibility in surgical robotics
ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year’s Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimpse to HRS attendees into the robot’s revolutionary clinical capabilities and “weekend” installation.
GenesisX represents the latest advance in endovascular surgical robotics, building upon the proven benefits of Robotic Magnetic Navigation while significantly enhancing accessibility for healthcare providers. The system features a compact and efficient design, incorporating magnetic shielding into its structure to eliminate the need for room-based shielding, reducing infrastructure requirements. GenesisX operates on standard 120/230V power, requires no structural anchoring, and features an
Stereotaxis will be located at Booth 1034 and will be featured during several events throughout the congress, including:
- Stereotaxis Investor Technology Demonstration: Friday April 25th at 12:00 PM PDT
- Joint Session with Africa Heart Rhythm Association on leveraging telerobotics to advance care in underserved communities: Saturday April 26th at 2:45 PM PDT
- Joint Session of HRS & Society for Cardiac Robotic Navigation (SCRN): April 27th at 12:45 PM PDT
“We are thrilled to bring GenesisX to HRS and allow the electrophysiology community to experience firsthand this cutting-edge innovation along with our expanding portfolio of proprietary catheters and digital technologies,” said David Fischel, Stereotaxis Chairman and CEO. “We look forward to engaging with the electrophysiology community at HRS, who, together with us, are pioneering the frontiers of medicine.”
GenesisX obtained CE Mark approval in Europe in 2024 and is currently under review for FDA 510(k) clearance in the United States. In addition to GenesisX, Stereotaxis will showcase its portfolio of compatible EP and vascular catheters, including the Map-iT™, MAGiC™, and EMAGIN™ product lines, as well as its advanced Synchrony™ and SynX™ digital lab technologies.
If you are interested in a meeting to learn more about GenesisX or other Stereotaxis technology, please contact info@Stereotaxis.com.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What are the key features of Stereotaxis GenesisX Robotic System showcased at HRS 2025?
What is the regulatory status of STXS GenesisX Robotic System in 2025?
Which catheter products will Stereotaxis (STXS) showcase alongside GenesisX at HRS 2025?
When and where will Stereotaxis demonstrate the GenesisX system at HRS 2025?
